(3R)-3-(4-(4-fluorophenyl)-1H-imidazol-2-yl)-1-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole | 1375085-94-1

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 哈马拉生物碱
• 英文名称: (3R)-3-(4-(4-fluorophenyl)-1H-imidazol-2-yl)-1-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole
• 英文别名: (1R,3R)-3-[5-(4-fluorophenyl)-1H-imidazol-2-yl]-1-(oxan-4-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole
• CAS: 1375085-94-1
• 化学式: C₂₅H₂₅FN₄O
• 分子量: 416.498
• InChiKey: FRWHMBLUCGXEQQ-FYYLOGMGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  31
• 可旋转键数：
  3
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  65.7
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  BOC-D-色氨酸 在 caesium carbonate 、 三氟乙酸 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 4.0h， 生成 (3R)-3-(4-(4-fluorophenyl)-1H-imidazol-2-yl)-1-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole
  参考文献：
  名称：

  The Discovery of MK-4256, a Potent SSTR3 Antagonist as a Potential Treatment of Type 2 Diabetes

  摘要：

  A structure-activity relationship study of the imidazolyl-beta-tetrahydrocarboline series identified MK-4256 as a potent, selective SSTR3 antagonist, which demonstrated superior efficacy in a mouse oGTT model. MK-4256 reduced glucose excursion in a dose-dependent fashion with maximal efficacy achieved at doses as low as 0.03 mg/kg po. As compared with glipizide, MK-4256 showed a minimal hypoglycemia risk in mice.

  DOI：

  10.1021/ml300063m

文献信息

• The Discovery of MK-4256, a Potent SSTR3 Antagonist as a Potential Treatment of Type 2 Diabetes
  作者：Shuwen He、Zhixiong Ye、Quang Truong、Shrenik Shah、Wu Du、Liangqin Guo、Peter H. Dobbelaar、Zhong Lai、Jian Liu、Tianying Jian、Hongbo Qi、Raman K. Bakshi、Qingmei Hong、James Dellureficio、Alexander Pasternak、Zhe Feng、Reynalda deJesus、Lihu Yang、Mikhail Reibarkh、Scott A. Bradley、Mark A. Holmes、Richard G. Ball、Rebecca T. Ruck、Mark A. Huffman、Frederick Wong、Koppara Samuel、Vijay B. Reddy、Stan Mitelman、Sharon X. Tong、Gary G. Chicchi、Kwei-Lan Tsao、Dorina Trusca、Margaret Wu、Qing Shao、Maria E. Trujillo、George J. Eiermann、Cai Li、Bei B. Zhang、Andrew D. Howard、Yun-Ping Zhou、Ravi P. Nargund、William K. Hagmann

  DOI：10.1021/ml300063m

  日期：2012.6.14

  A structure-activity relationship study of the imidazolyl-beta-tetrahydrocarboline series identified MK-4256 as a potent, selective SSTR3 antagonist, which demonstrated superior efficacy in a mouse oGTT model. MK-4256 reduced glucose excursion in a dose-dependent fashion with maximal efficacy achieved at doses as low as 0.03 mg/kg po. As compared with glipizide, MK-4256 showed a minimal hypoglycemia risk in mice.
• SAR exploration at the C-3 position of tetrahydro-β-carboline sstr3 antagonists
  作者：Shuwen He、Peter H. Dobbelaar、Liangqin Guo、Zhixiong Ye、Jian Liu、Tianying Jian、Quang Truong、Shrenik K. Shah、Wu Du、Hongbo Qi、Raman K. Bakshi、Qingmei Hong、James D. Dellureficio、Edward Sherer、Alexander Pasternak、Zhe Feng、Mikhail Reibarkh、Melissa Lin、Koppara Samuel、Vijay B. Reddy、Stan Mitelman、Sharon X. Tong、Gary G. Chicchi、Kwei-Lan Tsao、Dorina Trusca、Margaret Wu、Qing Shao、Maria E. Trujillo、Guillermo Fernandez、Donald Nelson、Patricia Bunting、Janet Kerr、Patrick Fitzgerald、Pierre Morissette、Sylvia Volksdorf、George J. Eiermann、Cai Li、Bei B. Zhang、Andrew D. Howard、Yun-Ping Zhou、Ravi P. Nargund、William K. Hagmann

  DOI：10.1016/j.bmcl.2016.02.022

  日期：2016.3

  MK-4256, a tetrahydro-beta-carboline sstr3 antagonist, was discontinued due to a cardiovascular (CV) adverse effect observed in dogs. Additional investigations revealed that the CV liability (QTc prolongation) was caused by the hERG off-target activity of MK-4256 and was not due to sstr3 antagonism. In this Letter, we describe our extensive SAR effort at the C3 position of the tetrahydro-beta-carboline structure. This effort resulted in identification of 5-fluoro-pyridin-2-yl as the optimal substituent on the imidazole ring to balance sstr3 activity and the hERG off-target liability. (C) 2016 Elsevier Ltd. All rights reserved.